significantTreatment update
Long-term CLUSTER extension confirms sustained canakinumab efficacy in TRAPS
TNF Receptor-Associated Periodic Syndrome →Summary
Gattorno et al. (2024) published the 72-week extension of the CLUSTER trial showing >94% of TRAPS patients achieved no or minimal disease activity on canakinumab, with 69.8% experiencing zero flares.
Related treatments
Source
Grade Aclinical trial extension
Long-term efficacy and safety of canakinumab in patients with TRAPS: results from a phase III trial
Gattorno M, Obici L, Calvo Penadés I, Kallinich T, Benseler S, Dekker E, Lévy J, De Benedetti F, Lachmann H · Arthritis Rheumatol · 2024
- •>94% achieved no or minimal disease activity during 72-week extension
- •69.8% had zero flares; 24.5% had one flare (vs baseline median 9/year)
- •No new safety findings with long-term canakinumab
More from TNF Receptor-Associated Periodic Syndrome
incrementalTreatment update
Tocilizumab case reports expand treatment options for refractory TRAPS
significantNew research
French national series quantifies AA amyloidosis severity in TRAPS
significantGenetic finding
INSAID classification system validated for TRAPS treatment decisions
incrementalepidemiology
R92Q prevalence in inflammatory disease cohorts higher than expected
ID: traps-update-0Type: treatment_updateImpact: significant